Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high‐fat diet
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary: Recent discoveries have revealed the key role of mTOR (target of rapamycin) in aging. Furthermore, rapamycin extends lifespan in mice, especially in female mice. Here, we treated obese male mice on high‐fat diet with rapamycin given intermittently: either weekly (once a week) or alternating bi‐weekly (three injections every other week). While only marginally reducing obesity, intermittent administration of rapamycin significantly extended lifespan. Significance was achieved for weekly treated group and for the three rapamycin‐received groups combined. In weekly treatment group, 100% mice were alive by the age of 2 years, whereas 60% of mice died in untreated group by this age. The effect of weekly treatment on survival was highly significant and cannot be fully explained by partial reduction in obesity. Alternating bi‐weekly treatments seem to be less effective than weekly treatment, although effects of additional factors (see ) may not be excluded. After one year of treatment, all survived mice were sacrificed 8 days after the last administration of rapamycin to avoid its direct interference with parameters examined. Fasting levels of cardiac and hepatic p‐S6, a marker of mTORC 1 activity, were lower in weekly treatment group compared with control mice. In contrast, levels of p‐Akt (S473), glucose, triglycerides and insulin were unchanged, whereas leptin and IGF‐1 tended to be lower. Thus, weekly treatment with rapamycin may slow down aging in obese male mice on high‐fat diet.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 3×
“mTOR (mammalian or mechanistic target of rapamycin) is involved in organismal aging (Blagosklonny & Hall, 2009; Stanfel et al., 2009; Kapahi et al., 2010; Sengupta et al., 2010b; Bjedov & Partridge, 2011; Zoncu et al., 2011; Cornu et al., 2012; Flynn et al., 2013; Johnson et al., 2013).”
BackgroundRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 6×
“Also, rapamycin extends lifespan in male mice to a lesser degree compared with female mice (Harrison et al., 2009; Miller et al., 2011), probably in part due to different sensitivity to rapamycin (Leontieva et al., 2012a).”
BackgroundResultInfluentialmTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676 · cited 1×
“mTOR (mammalian or mechanistic target of rapamycin) is involved in organismal aging (Blagosklonny & Hall, 2009; Stanfel et al., 2009; Kapahi et al., 2010; Sengupta et al., 2010b; Bjedov & Partridge, 2011; Zoncu et al., 2011; Cornu et al., 2012; Flynn et al., 2013; Johnson et al., 2013).”
BackgroundMetformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing
Sengupta, S., Peterson, T. R., Laplante, M., Oh, S., & Sabatini, D. M. (2010) · Nature · doi:10.1038/nature09584 · Cited by 646
Khamzina, L., Veilleux, A., Bergeron, S., & Marette, A. (2005) · Endocrinology · doi:10.1210/en.2004-0921 · Cited by 562 · cited 1×
“Furthermore, activated mTOR/S6K pathway can cause insulin resistance (Khamzina et al., 2005; Krebs et al., 2007).”
BackgroundRapamycin extends murine lifespan but has limited effects on aging
Neff, F., Flores-Dominguez, D., Ryan, D. P., Horsch, M., Schröder, S., Adler, T., Afonso, L. C., Aguilar-Pimentel, J. A., Becker, L., Garrett, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67674 · Cited by 374
Ramos, F. J., Chen, S. C., Garelick, M. G., Dai, D.-F., Liao, C.-Y., Schreiber, K. H., MacKay, V. L., An, E. H., Strong, R., Ladiges, W. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003802 · Cited by 349 · cited 4×
“…lifespan in mice and prevents age-related pathologies including cancer (Harrison et al., 2009; Miller et al., 2011; Anisimov et al., 2011b, 2010; Ramos et al., 2012; Wilkinson et al., 2012; Spong & Bartke, 2012; Selman & Partridge, 2012; Neff et al., 2013; Ye et al., 2013; Flynn et al., 2013;…”
BackgroundInfluentialAnisimov, V. N., Berstein, L. M., Popovich, I. G., Zabezhinski, M. A., Egormin, P. A., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Kovalenko, I. G., et al. (2011) · Aging · doi:10.18632/aging.100273 · Cited by 285 · cited 2×
“…that rapamycin extends lifespan in mice and prevents age-related pathologies including cancer (Harrison et al., 2009; Miller et al., 2011; Anisimov et al., 2011b, 2010; Ramos et al., 2012; Wilkinson et al., 2012; Spong & Bartke, 2012; Selman & Partridge, 2012; Neff et al., 2013; Ye et…”
BackgroundParadoxical suppression of cellular senescence by p53
Demidenko, Z. N., Korotchkina, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002298107 · Cited by 273 · cited 1×
“Inhibition of mTOR suppresses geroconversion from reversible arrest to senescence (Demidenko et al., 2010; Leontieva et al., 2012c, 2013a).”
BackgroundSelf-citationBlagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251 · cited 2×
“Albeit based on theoretic considerations (Blagosklonny, 2012b), the choice of treatment schedules was relatively arbitrary.”
BackgroundSelf-citationThe Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man
Krebs, M., Brunmair, B., Brehm, A., Artwohl, M., Szendroedi, J., Nowotny, P., Roth, E., Fürnsinn, C., Promintzer, M., Anderwald, C., et al. (2007) · Diabetes · doi:10.2337/db06-1016 · Cited by 230
Hypoxia suppresses conversion from proliferative arrest to cellular senescence
Leontieva, O. V., Natarajan, V., Demidenko, Z. N., Burdelya, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205690109 · Cited by 169 · cited 10×
“Also, rapamycin extends lifespan in male mice to a lesser degree compared with female mice (Harrison et al., 2009; Miller et al., 2011), probably in part due to different sensitivity to rapamycin (Leontieva et al., 2012a).”
BackgroundMethodResultSelf-citation
Cited by
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging
Kennedy, B. K., & Lamming, D. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.009 · Cited by 544
Targeting the biology of aging with mTOR inhibitors
Mannick, J. B., & Lamming, D. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00416-y · Cited by 372
High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice
van der Heijden, R. A., Sheedfar, F., Morrison, M. C., Hommelberg, P. P., Kor, D., Kloosterhuis, N. J., Gruben, N., Youssef, S. A., de Bruin, A., Hofker, M. H., et al. (2015) · Aging · doi:10.18632/aging.100738 · Cited by 288
Arriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar, H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12405 · Cited by 182
“…inhibition of mTORC1 signaling in adipose tissue may have significant implications for the treatment of obesity and diabetes, and may partially explain a recent report demonstrating beneficial effects of weekly rapamycin administration to mice on a high-fat diet (Leontieva et al., 2014).”
BackgroundInfluential
Metadata
- Authors
- Leontieva, O. V., Paszkiewicz, G. M., & Blagosklonny, M. V.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2014-03-22
- Volume
- 13
- Issue
- 4
- Pages
- 616-622
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W1991154833
- Cited by
- 78
- References
- 13
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.